Lantheus Medical Imaging, Inc., a global leader in developing,
manufacturing and distributing innovative diagnostic imaging agents,
entered into a strategic distribution arrangement with Beijing
Double-Crane Pharmaceutical Co., LTD. (Double-Crane), a leading
pharmaceutical company, for Definity Vial for (Perflutren Lipid
Microsphere) Injectable Suspension in the People’s Republic of China,
including Hong Kong S.A.R. and Macau S.A.R.
Showing posts with label Pharmacy. Show all posts
Showing posts with label Pharmacy. Show all posts
Monday, 27 February 2012
USPTO grants patent titled 'method of therapeutic administration of DHE' to MAP Pharma
The United States Patent and Trademark Office (USPTO) issued to the MAP
Pharmaceuticals' US Patent No. 8,119,639, titled "Method of Therapeutic
Administration of DHE to Enable Rapid Relief of Migraine while
Minimizing Side Effect Profile."
Elder Pharma & Combe launch Vagisil range of feminine personal hygiene products in India
Elder Pharmaceuticals Ltd, one of the fastest growing pharmaceutical
companies in the country, in association with New York based Combe Inc.,
a global brand leader in feminine care, has launched the Vagisil range
of feminine personal hygiene products today in India.
Vagisil has been a world leader in feminine care for over four decades and is the most trusted and well accepted brand in over 40 countries across the globe. Combe Inc., and Elder Pharma are introducing three key solutions to help Indian women with their feminine needs: Vagisil Anti-Itch Creme, Vagisil Intimate Feminine Wash and Vagisil Intimate Feminine Lubricant.
Vagisil has been a world leader in feminine care for over four decades and is the most trusted and well accepted brand in over 40 countries across the globe. Combe Inc., and Elder Pharma are introducing three key solutions to help Indian women with their feminine needs: Vagisil Anti-Itch Creme, Vagisil Intimate Feminine Wash and Vagisil Intimate Feminine Lubricant.
Saturday, 25 February 2012
BioSante Pharmaceuticals Announces FDA Approval for Bio-T-Gel
Company: BioSante Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.
Date of Approval: February 14, 2012
Treatment for: Hypogonadism -- Male
Bio-T-Gel (testosterone) is a once-daily transdermal testosterone gel for the treatment of male hypogonadism or low
testosterone levels. Date of Approval: February 14, 2012
Treatment for: Hypogonadism -- Male
FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome
Company: Corcept Therapeutics
Date of Approval: February 17, 2012
Treatment for: Cushing's Syndrome
Date of Approval: February 17, 2012
Treatment for: Cushing's Syndrome
Korlym
(mifepristone) is a cortisol receptor blocker indicated to control
hyperglycemia secondary to hypercortisolism in adult patients with
endogenous Cushing's syndrome who have type 2 diabetes mellitus or
glucose intolerance.
Sun Pharma to export generic version of cancer medicine Lipidox to US
The US drug
regulator said it will import generic version of the cancer drug Lipidox from Sun Pharma to meet a supply shortage. A generic drug has to get clearance from the US Food and Drug Administration
to be sold in the US market, but in this rare case, the drug regulator
agreed to import because of an acute shortage of the approved drug.
Analysts said the decision opens up opportunities for Indian drug generic makers. There are close to 287 essential drugs that are in short supply in the US.
Analysts said the decision opens up opportunities for Indian drug generic makers. There are close to 287 essential drugs that are in short supply in the US.
Indian pharma firm 'Panacea Biotec' launches drug against polio in Nigeria
A leading Indian pharmaceutical company has launched a polio vaccine, POLPROTEC in Nigeria to help combat the spread of polio in Africa's top oil producer.
To make the vaccine easily available, Panacea Biotec is partnering Emzor pharma which has a strong footprint across Nigeria. The country is still facing the challenge of polio virus.
To make the vaccine easily available, Panacea Biotec is partnering Emzor pharma which has a strong footprint across Nigeria. The country is still facing the challenge of polio virus.
During the launch, Panacea and Emzor made a public declaration of a
Joint Polio-Free Mission "To contribute towards achieving the goal of
global polio eradication and to ensure that no child will ever again be
paralyzed by WPV or Vaccine-Derived Polio Virus (VDPV)."
Friday, 24 February 2012
Wednesday, 22 February 2012
Cadila Pharma signs pact with Bactiguard to sell products for prevention of hospital acquired infection
Ahmedabad-based Cadila Pharmaceuticals has entered into an agreement with company Bactiguard to sell the Swedish drug firm's products in India. The products are aimed at prevention of hospital acquired infections.
Bactiguard provides solutions preventing hospital acquired infections, which are the fourth largest cause of death in the western world. The company has the technology to use thin noble metal coating that has antimicrobial and biocompatible properties that can be used on all sorts of medical devices. The company's product can reduce health cost for the governments and lower the use of antibiotics and save lives.
Bactiguard provides solutions preventing hospital acquired infections, which are the fourth largest cause of death in the western world. The company has the technology to use thin noble metal coating that has antimicrobial and biocompatible properties that can be used on all sorts of medical devices. The company's product can reduce health cost for the governments and lower the use of antibiotics and save lives.
Amrita Centre for Nanosciences unveils drug for neuro tumours
The Amrita Centre for Nanosciences unveiled what is said to be a wonder drug to treat neuro-endocrine tumours.
The drug, Nanophotomedicine, was launched at a three-day conference organised by the Amrita Centre for Nanosciences.
According to Koyakutty, the nanomedicine for neuro-endocrine tumours can eliminate tumour cells much more efficiently than the available therapies.
The drug, Nanophotomedicine, was launched at a three-day conference organised by the Amrita Centre for Nanosciences.
According to Koyakutty, the nanomedicine for neuro-endocrine tumours can eliminate tumour cells much more efficiently than the available therapies.
US to import cancer drug,Lipodox, from India
The United States said it will import cancer drug
manufactured in India to overcome the acute shortage of the medicine
used in treatment of ovarian, bone marrow and AIDS-related skin cancer.
Exercising its enforcement discretion, the Federal Drug Administration (FDA) said the chemotherapeutic drug Lipodox will be imported as an alternative to Doxil.
Exercising its enforcement discretion, the Federal Drug Administration (FDA) said the chemotherapeutic drug Lipodox will be imported as an alternative to Doxil.
Monday, 20 February 2012
Marico buys Paras personal care brands from Reckitt Benckiser
Marico has bought the personal care business of Paras Pharmaceuticals from UK
consumer goods giant Reckitt Benckiser, edging out Emami.
But two industry officials familiar with the negotiations said the
maker of parachute hair oil has paid Rs 600-650 crore for the
privately-held Paras Pharma's personal care brands such as Zatak
deodorant, Set Wet hair gel and Livon hair serum.
Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals
Par Pharmaceutical
Companies, Inc. (NYSE: PRX) announced that it has completed the
acquisition of privately-held Edict Pharmaceuticals Private Limited, an
India-based developer and manufacturer of generic pharmaceuticals.
Sunday, 19 February 2012
New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
Schering-Plough Corporation (NYSE: SGP) has announced the introduction
of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy
medicine in an easy-to-swallow liquid-filled capsule. Now available
over-the-counter, CLARITIN(R) Liqui-Gels(R) provide powerful liquid
relief for the worst allergy symptoms without causing drowsiness.
Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
Teijin Pharma Limited announced the European launch of TMX-67
(febuxostat), a novel drug discovered by for the treatment
of hyperuricemia in patients with gout.
Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that
Soliris(R) (eculizumab), its first-in-class complement inhibitor, has
been granted Orphan Medicinal Product Designation by the European
Commission for the treatment of patients with atypical Hemolytic Uremic
Syndrome (aHUS).
AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009.
AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009.
FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.
TikoMed AB, a biotechnology company focused on treatments for immune diseases and cell
therapies, announced that IBsolvMIR® has been granted orphan drug
designation for the prevention of graft rejection of pancreatic islet
transplantation by the U.S. Food and Drug Administration (FDA).
IBsolvMIR is a unique new treatment which could transform islet cell transplantation into a standard treatment for severe type 1 diabetes patients with unstable diabetic conditions. TikoMed's product IBsolvMIR improves the survival of transplanted cells by inhibiting a destructive immunological reaction and through stimulation of growth factors.
IBsolvMIR is a unique new treatment which could transform islet cell transplantation into a standard treatment for severe type 1 diabetes patients with unstable diabetic conditions. TikoMed's product IBsolvMIR improves the survival of transplanted cells by inhibiting a destructive immunological reaction and through stimulation of growth factors.
Subscribe to:
Posts (Atom)